A Multicentre, Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled Study With Open Label Extension to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 06 Jul 2017 Planned End Date changed from 28 Nov 2018 to 10 Apr 2019.
- 06 Jul 2017 Planned primary completion date changed from 1 Nov 2018 to 10 Apr 2019.
- 10 Jun 2017 Biomarkers information updated